How do you manage the challenges that accompany the narrowing therapeutic window for CD/LD? Given the evolving therapeutic toolkit—including the availability of fractionated CD/LD dosing formulation—what options go through your mind at this point?

How do you manage the challenges that accompany the narrowing therapeutic window for CD/LD? Given the evolving therapeutic toolkit—including the availability of fractionated CD/LD dosing formulation—what options go through your mind at this point?

How do you manage the challenges that accompany the narrowing therapeutic window for CD/LD? Given the evolving therapeutic toolkit—including the availability of fractionated CD/LD dosing formulation—what options go through your mind at this point?


Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

Laxman Bahroo, DO, FAAN

Laxman Bahroo, DO, FAAN

Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.